Continue reading this on our app for a better experience

Open in App
Home News Covid-19

Could this German company have the solution to sub-zero Covid-19 vaccine storage?

Bloomberg
Bloomberg • 1 min read
Could this German company have the solution to sub-zero Covid-19 vaccine storage?
The need to store the vaccines at sub-zero temperatures has proven a challenge for potential vaccine distribution.
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

CureVac NV, the German biotech company, said its experimental coronavirus vaccine may be able to overcome storage and distribution challenges that threaten to hinder the rollout of rival shots.

Data show CureVac’s messenger RNA vaccine remained stable for at least three months when stored at a standard refrigerator temperature of 5 degrees Celsius (41 degrees Fahrenheit), and for up to 24 hours as a ready-to-use shot when stored at room temperature, the company said Thursday.

Some vaccines, like the front-runner from Pfizer Inc. and BioNTech SE, must be kept at ultra-cold temperatures and require complex handling to remain viable. That storage requirement is an obstacle that will need to be tackled before the vaccine can be made broadly available, according to experts, and the deployment costs raise worries that poorer nations will be left behind.

CureVac said its stability study is ongoing, aimed at further evaluating the potential for a longer commercial shelf-life.

Speaking at an event Thursday, Anthony Fauci, the top U.S. infectious disease official, pointed to the next vaccines in the pipeline that won’t have the need to be stored at such cold temperatures.

×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.